INTRODUCTIONA main pathophysiological feature of glioblastoma (GBM) is widespread invasion of the brain parenchyma, rendering localized therapies ineffective. In addition, brain tumour initiating cells (BTIC) may repopulate the tumour site after initially effective treatments. Thus, the invasive tumour cell fraction is a strategic prime target for early anti-invasion therapies.
展开▼